Intralesional Vit. D as a cost effective modality for multiple warts: Case report

The cost effective approach for developing country ?

Authors

  • Dennis Henry Usha Memorial Skin and Eye Hospital, Bilaspur (Chhattisgarh), India.
  • Daniel Henry Usha Memorial Skin and Eye Hospital, Bilaspur (Chhattisgarh), India.

DOI:

https://doi.org/10.66344/jpad.33.3.2023.2290

Keywords:

wart, immunotherapy, vitd

Abstract

Warts are a non-cancerous epidermal growth of the skin and mucosal membrane viral disease caused by human papillomavirus (HPV). Sudden clearance of lesions occurs under 24 months in about 80% of cases, people still look for a cure as it is cosmetically unpleasant and sometimes  Destructive treatment of warts is a majorly used, like topical keratolytic, electrosurgery, cryosurgery or lasers. These modalities prove to be ineffective in providing good aesthetic outcomes and avoiding recurrences. In a resource-limited setting, the cost of the treatment a crucial role in managing the patient of warts. Vitamin D comes up as one of the most affordable options for immunotherapy of the same. Few research papers have proven Vitamin D topical therapy to be effective.We report the response of multiple cutaneous warts to intralesional Vitamin D3 injections.

References

Sterling JC, Handfield-Jones S, Hudson PM. British Association of Dermatologists. Guidelines for the management of cutaneous warts. Br J Dermatol. 2001;144:4–11

Gibbs S, Harvey I, Sterling J, Stark R. Local treatments for cutaneous warts: Systematic review. BMJ. 2002;325:461.

Savant SS, Gore D. Electrosurgery. In: Savant SS, Shah RA, Gore D, editors. Textbook and Atlas of Dermatosurgery and Cosmetology. Mumbai: ASCAD; 2005. pp. 305–14.

Bourke JF, Berth-Jones J, Hutchinson PE. Cryotherapy of common viral warts at intervals of 1, 2 and 3 weeks. Br J Dermatol. 1995;132:433–6.

Tan OT, Hurwitz RM, Stafford TJ. Pulsed dye laser treatment of recalcitrant verrucae: A preliminary report. Lasers Surg Med. 1993;13:127–37.

Gonçalves MA, Donadi EA. Immune cellular response to HPV: Current concepts. Braz J Infect Dis. 2004;8:1–9.

Nofal A, Nofal E. Intralesional immunotherapy of common warts: Successful treatment with mumps, measles and rubella vaccine. J Eur Acad Dermatol Venereol. 2010;24:1166–70.

Shaheen MA, Salem SA, Fouad DA, El-Fatah AA. Intralesional tuberculin (PPD) versus measles, mumps, rubella (MMR) vaccine in treatment of multiple warts: A comparative clinical and immunological study. Dermatol Ther. 2015;28:194–200.

Garg S, Baveja S. Intralesional immunotherapy for difficult to treat warts with Mycobacterium w vaccine. J Cutan Aesthet Surg. 2014;7:203–8.

Majid I, Imran S. Immunotherapy with intralesional Candida albicans antigen in resistant or recurrent warts: A study. Indian J Dermatol. 2013;58:360–5.

Rind T, Oiso N, Kawada A. Successful treatment of anogenital wart with a topical Vitamin D(3) Derivative in an infant. Case Rep Dermatol. 2010;2:46–49.

Imagawa I, Suzuki H. Successful treatment of refractory warts with topical Vitamin D3 derivative (maxacalcitol, 1alpha, 25-dihydroxy-22-oxacalcitriol) in 17 patients. J Dermatol. 2007;34:264–6.

Aktas H, Ergin C, Demir B, Ekiz Ö. Intralesional Vitamin D injection may be an effective treatment option for warts. J Cutan Med Surg. 2016;20:118–22.

Shalaby ME, Hasan MS, Elshorbagy MS, Abo Raya AR, Elsaie ML. Diagnostic and therapeutic implications of vitamin D deficiency in patients with warts: A case-controlled study. J Cosmet Dermatol. 2022 Mar;21(3):1135-1142. doi: 10.1111/jocd.14156. Epub 2021 Apr 25. PMID: 33860625.

Downloads

Published

2023-08-07

How to Cite

1.
Henry D, Henry D. Intralesional Vit. D as a cost effective modality for multiple warts: Case report: The cost effective approach for developing country ?. J Pak Assoc Dermatol [Internet]. 2023Aug.7 [cited 2026Apr.12];33(3):1137-9. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2290

Issue

Vol. 33 No. 3 (2023): July-September

Section

Case Reports

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.